Videos

It could take up to 10 years to develop new treatments for inflammatory bowel disease.

Andres Yarur, MD, of the Medical College of Wisconsin, comments on the chronic, progressive nature of ulcerative colitis and highlights special considerations for classifying patients based on disease severity.

A large proportion of IBS-C patients did not seek health care during the COVID-19 pandemic despite symptoms.

COVID-19 patients with liver injuries are at a higher risk of mortality or lengthier hospital stays.

C difficile and sepsis infections can be especially difficult to treat.

There is a substantial health care cost for CDI patients with sepsis.

The high-risk patient population is under-represented in new research and agents. Why characteristics set it apart from other cardiovascular diseases?

New data suggest 90 days following an initial ACS event is the greatest time of likelihood for another high-risk event. How can this inform cardiovascular research?

Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.

A cardiologist and wellness expert discusses new findings showing more than one-third of her peers were burnt out from experiences during the pandemic.

Role of imaging modalities in the diagnosis and monitoring of age-related macular degeneration (AMD).

Carl Regillo, MD and Diana Do, MD, describe the progressive nature of age-related macular degeneration (AMD) and differences between dry AMD and wet AMD.

New phase 2 data show the potential of the biologic in patients at risk of acute pancreatitis progression, but with a need for better variable understanding.

Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.

Investigators discuss observed outcomes in females with high-risk PCI treatment, and their continued underrepresentation in pharmacologic studies.

Prescription rates of buprenorphine and opioid analgesics for OUD fell during the COVID-19 pandemic for new patients, but existing treatment was not affected.

Experts discuss patient factors and decision-making in choosing therapies for sickle cell disease.

Key opinion leaders focus on the use of crizanlizumab for painful crisis frequency in sickle cell disease.

A panel of experts in schizophrenic psychiatric care share their thoughts on the practice, patients, and treatment based on their years of experience.

Dr Marla Dubinsky describes the rationale for using a treat-to-target approach when managing patients with inflammatory bowel disease and explains how she establishes goals of therapy for her patients.

Marla Dubinsky, MD, highlights currently available biologic therapies used to treat inflammatory bowel disease and describes where each option best fits into the therapeutic landscape.

Bempedoic acid monotherapy and its combination with ezetimibe for lipid lowering in patients intolerant to statins.

Role of dietary and lifestyle modifications as part of lipid management.

James Januzzi, MD, and Javed Butler, MD, MPH, MBA, discuss emerging agents, vericiguat and intravenous (IV) iron, in the treatment landscape for heart failure with reduced ejection fraction and advice for community physicians managing patients with heart failure.

A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.